The AML1/MTG8 Fusion Transcript in t(8;21) Positive AML and its Implication for the Detection of Minimal Residual Disease

References

• Fourth international workshop on chromosomes in leukemia (1984). Cancer Genet Cytogenet, 11, 249–360.
   PubMed Web of Science ®Google Scholar
• Rowley, J. D. (1990). Recurring chromosome abnormalities in leukemia and lymphoma, Semin Hematol, 27, 122–136.
   PubMed Web of Science ®Google Scholar
• Miyoshi, H., Kozu, T., Shimizu, K., Enomoto, K., Maseki, N., Kaneko, Y., Kamada, N. and Ohki, M. (1993). The t(8;21) translocation in acute myeloid leukemia results in production of an AML1-MTG8 fusion transcript, EMBO J, 12, 2715–2721.
   PubMed Web of Science ®Google Scholar
• Nucifora, G. and Rowley, J. D. (1995). AML1 and the 8;21 and 3;21 translocations in acute and chronic myeloid leukemia, Blood, 86, 1–14.
   PubMed Web of Science ®Google Scholar
• Tanaka, T., Tanaka, K., Ogawa, S., Kurokawa, M., Mitani, K., Nishida, J., Shibata, Y., Yazaki, Y. and Hirai, H. (1995). An acute myeloid leukemia gene, AML1, regulates hemopoietic myeloid cell differentiation and transcriptional activation antagonistically by two alternative spliced forms, EMBO J, 14, 341–350.
   PubMed Web of Science ®Google Scholar
• Erickson, P., Gao, J., Chang, K. S., Look, T., Whisenant, E., Raimondi, S., Lasher, R., Trujillo, J., Rowley, J. and Drabkin, H. (1992). Identification of breakpoints in t(8;21) acute myelogenous leukemia and isolation of a fusion transcript, AML1/ETO, with similarity to Drosophila segmentation gene, runt, Blood, 80, 1825–1831.
   PubMed Web of Science ®Google Scholar
• Meyers, S., Downing, J. R. and Hiebert, S. W. (1993). Identification of AML-1 and the (8;21) translocation protein (AML-1/ETO) as sequence-specific DNA-binding proteins: the runt homology domain is required for DNA binding and protein—protein interactions, Mol Cell Biol, 13, 6336–6345.
   PubMed Web of Science ®Google Scholar
• Downing, J. R. (1999). The AML1-ETO chimaeric transcription factor in acute myeloid leukaemia: biology and clinical significance, Br J Haematol, 106, 296–308.
   PubMed Web of Science ®Google Scholar
• Nuchprayoon, I., Meyers, S., Scott, L. M., Suzow, J., Hiebert, S. and Friedman, A. D. (1994). PEBP2/CBF, the murine homolog of the human myeloid AML1 and PEBP2 beta/CBF beta proto-oncoproteins, regulates the murine myeloperoxidase and neutrophil elastase genes in immature myeloid cells, Mol Cell Biol, 14, 5558–5568.
   PubMed Web of Science ®Google Scholar
• Frank, R., Zhang, J., Uchida, H., Meyers, S., Hiebert, S. W. and Nimer, S. D. (1995). The AML1/ETO fusion protein blocks transactivation of the GM-CSF promoter by AML1B, Oncogene, 11, 2667–2674.
   PubMed Web of Science ®Google Scholar
• Uchida, H., Zhang, J. and Nimer, S. D. (1997). AML1A and AML1B can transactivate the human IL-3 promotor, J Immunol, 158, 2251–2258.
   PubMed Web of Science ®Google Scholar
• Zhang, D. E., Hetherington, C. J., Meyers, S., Rhoades, K. L., Larson, C. J., Chen, H. M., Hiebert, S. W. and Tenen, D. G. (1996). CCAAT enhancer-binding protein (C/EBP) and AML1 (CBFalpha2) synergistically activate the macrophage colony-stimulating factor receptor promoter, Mol Cell Biol, 16, 1231–1240.
   PubMed Web of Science ®Google Scholar
• Strout, M. P., Marcucci, G., Caligiuri, M. A. and Bloomfield, C. D. (1999). Core-binding factor (CBF) and MLL-associated primary acute myeloid leukemia: biology and clinical implications, Ann Hematol, 78, 251–264.
   PubMed Web of Science ®Google Scholar
• Cockerill, P. N., Osborne, C. S., Bert, A. G. and Grotto, R. J. (1996). Regulation of GM-CSF gene transcription by core-binding factor, Cell Growth Differ, 7, 917–922.
   PubMedGoogle Scholar
• Wang, Q., Stacy, T., Binder, M., Marin Padilla, M., Sharpe, A. H. and Speck, N. A. (1996). Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis, Proc Natl Acad Sci USA, 93, 3444–3449.
   PubMed Web of Science ®Google Scholar
• Okuda, T., van Deursen, J., Hiebert, S. W., Grosveld, G. and Downing, J. R. (1996). AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis, Cell, 84, 321–330.
   PubMed Web of Science ®Google Scholar
• Okada, H., Watanabe, T., Niki, M., Takano, H., Chiba, N., Yanai, N., Tani, H., Hibino, H., Asano, S., Mucenski, M. L., Ito, Y., Noda, T. and Satake, M. (1998). AML1(-/-) embryos do not express certain hematopoiesis-related gene transcripts including those of the PU.1 gene, Oncogene, 17, 2287–2293.
   PubMed Web of Science ®Google Scholar
• Okuda, T., Takeda, K., Fujita, Y., Nishimura, M., Yagyu, S., Yoshida, M., Akira, S., Downing, J. R. and Abe, T. (2000). Biological characteristics of the leukemia-associated transcriptional factor AML1 disclosed by hematopoietic rescue of AML1-deficient embryonic stem cells by using a knock-in strategy, Mol Cell Biol, 20, 319–328.
   PubMed Web of Science ®Google Scholar
• Yergeau, D. A., Hetherington, C. J., Wang, Q., Zhang, P., Sharpe, A. H., Binder, M., Marin-Padilla, M., Tenen, D. G., Speck, N. A. and Zhang, D. E. (1997). Embryonic lethality and impairment of hematopoiesis in mice heterozygous for an AML1-ETO fusion gene, Nat Genet, 15, 303–306.
   PubMed Web of Science ®Google Scholar
• Wang, Q., Stacy, T., Miller, J. D., Lewis, A. F., Gu, T. L., Huang, X., Bushweller, J. H., Bories, J. C., Alt, F. W., Ryan, G., Liu, P. P., Wynshaw-Boris, A., Binder, M., Marin-Padilla, M., Sharpe, A. H. and Speck, N. A. (1996). The CBFbeta subunit is essential for CBFalpha2 (AML1) function in vivo, Cell, 87, 697–708.
   PubMed Web of Science ®Google Scholar
• Castilla, L. H., Wijmenga, C., Wang, Q., Stacy, T., Speck, N. A., Eckhaus, M., Marin-Padilla, M., Collins, F. S., Wynshaw-Boris, A. and Liu, P. P. (1996). Failure of embryonic hematopoiesis and lethal hemorrhages in mouse embryos heterozygous for a knocked-in leukemia gene CBFB-MYH11, Cell, 87, 687–696.
   PubMed Web of Science ®Google Scholar
• Okuda, T., Cai, Z., Yang, S., Lenny, N., Lyu, C. J., van Deursen, J. M., Harada, H. and Downing, J. R. (1998). Expression of a knocked-in AML1-ETO leukemia gene inhibits the establishment of normal definitive hematopoiesis and directly generates dysplastic hematopoietic progenitors, Blood, 91, 3134–3143.
   PubMed Web of Science ®Google Scholar
• Erickson, P. F., Robinson, M., Owens, G. and Drabkin, H. A. (1994). The ETO portion of acute myeloid leukemia t(8;21) fusion transcript encodes a highly evolutionarily conserved, putative transcription factor, Cancer Res, 54, 1782–1786.
   PubMed Web of Science ®Google Scholar
• Erickson, P. F., Dessev, G., Lasher, R. S., Philips, G., Robinson, M. and Drabkin, H. A. (1996). ETO and AML1 phosphoproteins are expressed in CD34+ hematopoietic progenitors: implications for t(8;21) leukemogenesis and monitoring residual disease, Blood, 88, 1813–1823.
   PubMed Web of Science ®Google Scholar
• Era, T., Asou, N., Yamaguchi, K., Yamasaki, H., Kamada, N., Nishikawa, S. and Takatsuki, K. (1995). Expression of AML1 and ETO Transcripts in hematopoietic cells. Leukemia, 9 (Suppl 1), S26–S28.
   PubMedGoogle Scholar
• Gelmetti, V., Zhang, J., Fanelli, M., Minucci, S., Pelicci, P. G. and Lazar, M. A. (1998). Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO, Mol Cell Biol, 18, 7185–7191.
   PubMed Web of Science ®Google Scholar
• Lutterbach, B., Westendorf, J. J., Linggi, B., Patten, A., Moniwa, M., Davie, M., Huynh, J. R., Bardwell, K. D., Lavinsky, V. J., Rosenfeld, R. M., Glass, C., Seto, E. and Hiebert, S. W. (1998). ETO, a target of t(8;21) in acute leukemia, interacts with the N-CoR and mSin3 corepressors, Mol Cell Biol, 18, 7176–7184.
   PubMed Web of Science ®Google Scholar
• Wang, J., Hoshino, T., Redner, R. L., Kajigaya, S. and Liu, J. M. (1998). ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDACl complex, Proc Natl Acad Sci USA, 95, 10860–10865.
   PubMed Web of Science ®Google Scholar
• Meyers, S., Lenny, N. and Hiebert, S. W. (1995). The t(8;21) fusion protein interferes with AML-1B-dependent transcriptional activation, Mol Cell Biol, 15, 1974–1982.
   PubMed Web of Science ®Google Scholar
• Lutterbach, B., Sun, D., Schuetz, J. and Hiebert, S. W. (1998). The MYND motif is required for repression of basal transcription from the multidrug resistance 1 promotor by the t(8;21) fusion protein, Mol Cell Biol, 18, 3604–3611.
   PubMed Web of Science ®Google Scholar
• Westendorf, J. J., Yamamoto, C. M., Lenny, N., Downing, J. R., Selsted, M. E. and Hiebert, S. W. (1998). The t(8;21) fusion product, AML1-ETO, associates with C/EBP-alpha-dependent transcription and blocks granulocytic differentiation, Mol Cell Biol, 18, 322–333.
   PubMed Web of Science ®Google Scholar
• Klampfer, L., Zhang, J., Zelenetz, A. O., Uchida, H. and Nimer, S. D. (1996). The AML1/ETO fusion protein activates transcription of BCL-2, Proc Natl Acad Sci USA, 93, 14059–14064.
   PubMed Web of Science ®Google Scholar
• Kohzaki, H., Ito, K., Huang, G., Wee, H. J., Murakami, Y. and Ito, Y. (1999). Block of granulocytic differentiation of 32Dcl3 cells by AML1/ETO(MTG8) but not by highly expressed Bcl-2, Oncogene, 18, 4055–4062.
   PubMed Web of Science ®Google Scholar
• Krauter, J., Ganser, A., Bergmann, L., Raghavachar, A., Hoelzer, D., Lübbert, M., Schlimok, G., Arnold, R., Kirchner, H., Port, M. and Heil, G. (1999). Association between structural and numerical chromosomal aberrations in acute myeloblastic leukemia: a study by RT-PCR and FISH in 447 patients with de novo AML, Ann Hematol, 78, 265–269.
   PubMed Web of Science ®Google Scholar
• Nucifora, G., Dickstein, J. I., Torbenson, V., Roulston, D., Rowley, J. D. and Vardiman, J. W. (1994). Correlation between cell morphology and expression of the AML1/ETO chimeric transcript in patients with acute myeloid leukemia without the t(8;21), Leukemia, 8, 1533–1538.
   PubMed Web of Science ®Google Scholar
• Hurwitz, C. A., Raimondi, S. C., Head, D., Krance, R., Mirro, J., Kalwinsky, D. K., Ayers, G. D. and Behm, F. G. (1992). Distinctive immunophenotypic features of t(8;21)(q22;q22) acute myeloblastic leukemia in children, Blood, 80, 3182–3188.
   PubMed Web of Science ®Google Scholar
• Porwit-MacDonald, A., Janossy, G., Ivory, G., Swirsky, D., Peters, R., Wheatley, K., Walker, H., Turker, A., Goldstone, A. H. and Burnett, A. (1996). Leukemia-associated changes identified by quantitative flow cytometry. IV. CD34 overexpression in acute myelogenous leukemia M2 with t(8;21), Blood, 87, 1162–1169.
   PubMed Web of Science ®Google Scholar
• Andrieu, V., Radford Weiss, I., Troussard, X., Chane, C., Valensi, F., Guesnu, M., Haddad, E., Viguier, F., Dreyfus, F., Varet, B., Flandrin, G. and Macintyre, E. (1996). Molecular detection of t(8;21)/AML1-ETO in AML M1/M2: correlation with cytogenetics, morphology and immunophenotype, Br J Haematol, 92, 855–865.
   PubMed Web of Science ®Google Scholar
• Schoch, C., Haase, D., Haferlach, T., Gudat, H., Buchner, T., Freund, M., Link, H., Lengfelder, E., Wandt, H., Sauerland, M. C., Loffler, H. and Fonatsch, C. (1996) Fifty-one patients with acute myeloid leukemia and translocation t(8;21)(q22;q22): an additional deletion in 9q is an adverse prognostic factor, Leukemia, 10, 1288–1295.
   PubMed Web of Science ®Google Scholar
• Britos Vray, M., Sacchi, N. and Friedman, A. D. (1996). DNA-binding domain of AML1, expressed in t(8;21) and t(3;21) myeloid leukemias, inhibits PEBP2/CBF DNA-binding but is not sufficient to transform 32D cl3 myeloid cells, Leukemia, 10, 984–990.
   PubMed Web of Science ®Google Scholar
• Grimwade, D., Walker, H., Oliver, F., Wheatley, K., Harrison, C., Harrison, G., Rees, J., Hann, I., Stevens, R., Burnett, A. and Goldstone, A. (1998). The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 trial, Blood, 92, 2322–2333.
   PubMed Web of Science ®Google Scholar
• Bloomfield, C. D., Lawrence, D., Byrd, J. C., Carrol, A., Pettenati, M. J., Tantravahi, R., Patil, S. R., Davey, F. R., Berg, D. T., Schiffer, C. A., Arthur, D. C. and Mayer, R. J. (1998). Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype, Cancer Res, 58, 4173–4179.
   PubMed Web of Science ®Google Scholar
• Baer, M. R., Stewart, C. C., Lawrence, D., Arthur, D. C., Byrd, J. C., Davey, F. R., Schiffer, C. A. and Bloomfield, C. D. (1997). Expression of the neural cell adhesion molecule CD56 is associated with short remission duration and survival in acute myeloid leukemia with t(8;21)(q22;q22), Blood, 90, 1643–1648.
   PubMed Web of Science ®Google Scholar
• Byrd, J. C., Weiss, R. B., Arthur, D. C., Lawrence, D., Baer, M. R., Davey, F., Trikha, E. S., Caroll, A. J., Tantravahi, R., Qumsiyeh, M., Patil, S. R., Moore, J. O., Mayer, R. J., Schiffer, C. A. and Bloomfield, C. D. (1997). Extramedullary leukemia adversely affects hematologic complete remission rate and overall survival in patients with t(8;21)(q22;q22): results from Cancer and Leukemia Group B 8461, J Clin Oncol, 15, 466–475.
   PubMed Web of Science ®Google Scholar
• Downing, J. R., Head, D. R., Curcio Brint, A. M., Hulshof, M. G., Motroni, T. A., Raimondi, S. C., Carroll, A. J., Drabkin, H. A., Willman, C., Theil, K. S., Civin, C. I. and Erickson, P. (1993). An AML1/ETO fusion transcript is consistently detected by RNA-based polymerase chain reaction in acute myelogenous leukemia containing the (8;21)(q22;q22) translocation, Blood, 81, 2860–2865.
   PubMed Web of Science ®Google Scholar
• Hagemeijer, A., De Klein, A., Wijsman, A., Van Meerten, J., de Greef, G. E. and Sacchi, N. (1998). Development of an interphase fluorescent in situ hybridization (FISH) test to detect t(8;21) in AML patients, Leukemia, 12, 96–101.
   PubMed Web of Science ®Google Scholar
• Shimizu, K., Miyoshi, H., Kozu, T., Nagata, J., Enomoto, K., Maseki, N., Kaneko, Y. and Ohki, M. (1992). Consistent disruption of the AML1 gene occurs within a single intron in the t(8;21) chromosomal translocation, Cancer Res, 52, 6945–6948.
   PubMed Web of Science ®Google Scholar
• Kozu, T., Miyoshi, H., Shimizu, K., Maseki, N., Kaneko, Y., Asou, H., Kamada, N. and Ohki, M. (1993). Junctions of the AML1/MTG8(ETO) fusion are constant in t(8;21) acute myeloid leukemia detected by reverse transcription polymerase chain reaction, Blood, 82, 1270–1276.
   PubMed Web of Science ®Google Scholar
• Tighe, J. E., Daga, A. and Calabi, F. (1993). Translocation breakpoints are clustered on both chromosome 8 and chromosome 21 in the t(8;21) of acute myeloid leukemia, Blood, 81, 592–596.
   PubMed Web of Science ®Google Scholar
• de Greef, G. E., Hagemeijer, A., Morgan, R., Wijsman, J., Hoefsloot, L. H., Sandberg, A. A. and Sacchi, N. (1995). Identical fusion transcript associated with different breakpoints in the AML1 gene in simple and variant t(8;21) acute myeloid leukemia, Leukemia, 9, 282–287.
   PubMed Web of Science ®Google Scholar
• Mitterbauer, M., Kusec, R., Schwarzinger, I., Haas, O. A., Lechner, K. and Jaeger, U. (1998). Comparison of karyotype analysis and RT-PCR for AML1/ETO in 204 unselected patients with AML, Ann Hematol, 76, 139–143.
   PubMed Web of Science ®Google Scholar
• Langabeer, S. E., Walker, H., Rogers, J. R., Burnett, A. K., Wheatley, K., Swirsky, D., Goldstone, A. H. and Linch, D. C. (1997). Incidence of AML1/ETO fusion transcripts in patients entered into the MRC AML trials. MRC Adult Leukaemia Working Party, Br J Haematol, 99, 925–928.
   PubMed Web of Science ®Google Scholar
• Krauter, J., Peter, W., Pascheberg, U., Heinze, B., Bergmann, L., Hoelzer, D., Lübbert, M., Schlimok, G., Arnold, R., Kirchner, H., Port, M., Ganser, A. and Heil, G. (1998). Detection of karyotypic aberrations in acute myeloblastic leukaemia: A prospective comparison between PCR/FISH and standard cytogenetics in 140 patients with de novo AML, Br J Haematol, 103, 72–78.
   PubMed Web of Science ®Google Scholar
• Yin, J. A. and Tobal, K. (1999). Detection of minimal residual disease in acute myeloid leukaemia: methodologies, clinical and biological significance, Br J Haematol, 106, 578–590.
   PubMed Web of Science ®Google Scholar
• Nucifora, G., Larson, R. A. and Rowley, J. D. (1993). Persistence of the 8;21 translocation in patients with acute myeloid leukemia type M2 in long-term remission, Blood, 82, 712–715.
   PubMed Web of Science ®Google Scholar
• Saunders, M. J., Tobal, K. and Yin, J. A. (1994). Detection of t(8;21) by reverse transcriptase polymerase chain reaction in patients in remission of acute myeloid leukaemia type M2 after chemotherapy or bone marrow transplantation, Leuk Res, 18, 891–895.
   PubMed Web of Science ®Google Scholar
• Miyamoto, T., Nagafuji, K., Akashi, K., Harada, M., Kyo, T., Akashi, T., Takenaka, K., Mizuno, S., Gondo, H., Okamura, T., Dohy, H. and Niho, Y. (1996). Persistence of multipotent progenitors expressing AML1/ETO transcripts in long-term remission patients with t(8;21)acute myelogenous leukemia, Blood, 87, 4789–4796.
   PubMed Web of Science ®Google Scholar
• Saunders, M. J., Brereton, M. L., Adams, J. A., Tobal, K. and Liu Yin, J. A. (1997). Expression of AML1/MTG8 transcripts in clonogenic cells grown from bone marrow of patients in remission of acute myeloid leukaemia with t(8;21), Br J Haematol, 99, 921–924.
   PubMed Web of Science ®Google Scholar
• Jurlander, J., Caligiuri, M. A., Ruutu, T., Baer, M. R., Strout, M. P., Oberkircher, A. R., Hoffmann, L., Ball, E. D., Frei Lahr, D. A., Christiansen, N. P., Block, A. M., Knuutila, S., Herzig, G. P. and Bloomfield, C. D. (1996). Persistence of the AML1/ETO fusion transcript in patients treated with allogeneic bone marrow transplantation for t(8;21) leukemia, Blood, 88, 2183–2191.
   PubMed Web of Science ®Google Scholar
• Kusec, R., Laczika, K., Knobl, P., Friedl, J., Greinix, H., Kahls, P., Linkesch, W., Schwarzinger, I., Mitterbauer, G., Purtscher, B., Haas, O., Lechner, K. and Jaeger, K. (1994). AML1/ETO fusion mRNA can be detected in remission blood samples of all patients with t(8;21) acute myeloid leukemia after chemotherapy or autologous bone marrow transplantation, Leukemia, 8, 735–739.
   PubMed Web of Science ®Google Scholar
• Kwong, Y. L., Chan, V., Wong, K. F. and Chan, T. K. (1995). Use of the polymerase chain reaction in the detection of AML1/ETO fusion transcript in t(8;21), Cancer, 75, 821–825.
   PubMed Web of Science ®Google Scholar
• Satake, N., Maseki, N., Kozu, T., Sakashita, A., Kobayashi, H., Sakurai, M., Ohki, M. and Kaneko, Y. (1995). Disappearance of AML1-MTG8(ETO) fusion transcript in acute myeloid leukaemia patients with t(8;21) in long-term remission, Br J Haematol, 91, 892–898.
   PubMed Web of Science ®Google Scholar
• Sakata, N., Okamura, T., Inoue, M., Yumura-Yagi, K., Hara, J., Tawa, A., Kodera, U., Sako, M. and Kawa-Ha, K. (1997). Rapid disappearance of AML1/ETO fusion transcripts in patients with t(8;21) acute myeloid leukemia following bone marrow transplantation and chemotherapy, Leuk Lymphoma, 26, 141–152.
   PubMed Web of Science ®Google Scholar
• Morschhauser, F., Cayuela, J. M., Martini, S., Baruchel, A., Rousselot, P., Socie, G., Berthou, P., Jouet, J. P., Straetmans, N., Sigaux, F., Fenaux, P. and Preudhomme, C. (2000). Evaluation of minimal residual disease using reverse-transcription polymerase chain reaction int (8;21) acute myeloid leukemia: A multicenter study of 51 patients, J Clin Oncol, 18, 788.
   PubMed Web of Science ®Google Scholar
• Siebert, P. D. and Larrick, J. W. (1992). Competitive PCR, Nature, 359, 557–558.
   PubMed Web of Science ®Google Scholar
• Cross, N. C. P., Feng, L., Chase, A., Bungey, J., Hughes, T. P. and Goldman, J. M. (1993). Competitive polymerase chain reaction to estimate the number of of bcr-abl transcripts in chronic myeloid leukemia patients after bone marrow transplantation, Blood, 82, 1929–1936.
   PubMed Web of Science ®Google Scholar
• Meijerink, J. P., Smetsers, T. F., Raemaekers, J. M., Bogman, M. J., De Witte, T. and Mensink, E. J. (1993). Quantitation of follicular non Hodgkin's lymphoma cells carrying t(14;18) by competitive polymerase chain reaction, Br J Haematol, 84, 250–256.
   PubMed Web of Science ®Google Scholar
• Brisco, M. J., Condon, J., Hughes, E., Neoh, S. H., Sykes, P. J., Seshadri, R., Toogood, I., Waters, K., Tauro, G., Ekert, H. and Morley, A. A. (1994). Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of induction, Lancet, 343, 196–200.
   PubMed Web of Science ®Google Scholar
• Cross, C. P. (1995). Quantitative PCR techniques and applications, Br J Haematol, 89, 693–697.
   PubMed Web of Science ®Google Scholar
• Tobal, K. and Yin, J. A. (1996). Monitoring of minimal residual disease by quantitative reverse transcriptase-polymerase chain reaction for AML1-MTG8 transcripts in AML-M2 with t(8;21), Blood, 88, 3704–3709.
   PubMed Web of Science ®Google Scholar
• Tobal, K., Newton, J., Macheta, M., Chang, J., Morgenstern, G., Evans, P. A., Morgan, G., Lucas, G. S. and Liu Yin, J. A. (2000). Molecular quantitation of minimal residual disease in acute myeloid leukemia with t(8;21) can identify patients in durable remission and predict clinical relapse, Blood, 95, 815–819.
   PubMed Web of Science ®Google Scholar
• Muto, A., Mori, S., Matsushita, H., Awaya, N., Ueno, H., Takayama, N., Okamoto, S., Kizaki, M. and Ikeda, Y. (1996). Serial quantification of minimal residual disease of t(8;21) acute myelogenous leukaemia with RT-competitive PCR assay, Br J Haematol, 95, 85–94.
   PubMed Web of Science ®Google Scholar
• Miyamoto, T., Nagafuji, K., Harada, M., Eto, T., Fujisaki, T., Kubota, A., Akashi, K., Mizuno, S., Takenaka, K., Kanaji, T. et al. (1995). Quantitative analysis of AML1/ETO transcripts in peripheral blood stem cell harvests from patients with t(8;21) acute myelogenous leukaemia, Br J Haematol, 91, 132–138.
   PubMed Web of Science ®Google Scholar
• Förster, V. T. (1948). Zwischenmolekulare Energiewanderung und Fluoreszenz, Annals of Physics (Leipzig), 2, 55–75.
   Web of Science ®Google Scholar
• Gibson, U. E. M., Heid, C. A. and Williams, M. P. (1996). A novel method for real time quantitative RT-PCR, Genome Res, 6, 995–1001.
   PubMed Web of Science ®Google Scholar
• Heid, C. A., Stevens, J., Livak, K. J. and Williams, M. P. (1996). Real time quantitative PCR, Genome Res, 6, 986–994.
   PubMed Web of Science ®Google Scholar
• Mensink, E., van de Locht, A., Schattenberg, A., Linders, E., Schaap, N., Geurts van Kessel, A. and De Witte, T. (1998). Quantitation of minimal residual disease in Philadelphia chromosome positive chronic myeloid leukaemia using real-time quantitative RT-PCR, Br J Haematol, 102, 768–774.
   PubMed Web of Science ®Google Scholar
• Gerard, C. J., Olsson, K., Ramanathan, R., Reading, C. and Hanania, E. G. (1998). Improved quantitation of minimal residual disease in multiple myeloma using real-time polymerase chain reaction and plasmid-DNA complementarity determining region III standards, Cancer Res, 58, 3957–3964.
   PubMed Web of Science ®Google Scholar
• Pongers-Willemse, M. J., Verhagen, O. J., Tibbe, G. J., Wijkhuijs, A. J., de Haas, V., Roovers, E., van der Schoot, C. E. and van Dongen, J. J. (1998). Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes, Leukemia, 12, 2006–2014.
   PubMed Web of Science ®Google Scholar
• Pallisgaard, N., Clausen, N., Schroder, H. and Hokland, P. (1999). Rapid and sensitive minimal residual disease detection in acute leukemia by quantitative real-time RT-PCR exemplified by t(12;21) TEL-AML1 fusion transcript, Genes Chromosomes Cancer, 26, 355–365.
   PubMed Web of Science ®Google Scholar
• Wattjes, M. P., Krauter, J., Nagel, S., Heidenreich, O., Ganser, A. and Heil, G. (2000). Comparison of nested competitive RT-PCR and real-time RT-PCR for the detection and quantification of AML1/MTG8 fusion transcripts in t(8;21) positive acute myelogenous leukemia, Leukemia, 14, 329–335.
   PubMed Web of Science ®Google Scholar
• Marcucci, G., Livak, K. J., Bi, W., Strout, M. P., Bloomfield, C. D. and Caligiuri, M. A. (1998). Detection of minimal residual disease in patients with AML1/ETO-associated acute myeloid leukemia using a novel quantitative reverse transcription polymerase chain reaction assay, Leukemia, 12, 1482–1489.
   PubMed Web of Science ®Google Scholar
• Krauter, J., Wattjes, M. P., Nagel, S., Heidenreich, O., Krug, U., Kafert, S., Bunjes, D., Bergmann, L., Ganser, A. and Heil, G. (1999). Real-time RT-PCR for the detection and quantification of AML1/MTG8 fusion transcripts in t(8;21)-positive AML patients, Br J Haematol, 107, 80–85.
   PubMed Web of Science ®Google Scholar
• Fujimaki, S., Funato, T., Harigae, H., Imaizumi, M., Suzuki, H., Kaneko, Y., Miura, Y. and Sasaki, T. (2000). A quantitative reverse transcriptase polymerase chain reaction method for the detection of leukaemic cells with t(8;21) in peripheral blood, Eur J Haematol, 64, 252–258.
   PubMed Web of Science ®Google Scholar
• Sugimoto, T., Das, H., Imoto, S., Murayama, T., Gomyo, H., Chakraborty, S., Taniguchi, R., Isobe, T., Nakagawa, T., Nishimura, R. and Koizumi, T. (2000). Quantitation of minimal residual disease in t(8;21)-positive acute myelogenous leukemia patients using real-time quantitative RT-PCR, Am J Hematol, 64, 101–106.
   PubMed Web of Science ®Google Scholar